Bruton's kinase inhibitors for the treatment of immunological diseases: current status and perspectives
E Robak, T Robak - Journal of Clinical Medicine, 2022 - mdpi.com
The use of Bruton's tyrosine kinase (BTK) inhibitors has changed the management of
patients with B-cell lymphoid malignancies. BTK is an important molecule that interconnects …
patients with B-cell lymphoid malignancies. BTK is an important molecule that interconnects …
Determinants and biomarkers of progression independent of relapses in multiple sclerosis
Clinical, pathological, and imaging evidence in multiple sclerosis (MS) suggests that a
smoldering inflammatory activity is present from the earliest stages of the disease and …
smoldering inflammatory activity is present from the earliest stages of the disease and …
A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis
Bruton's tyrosine kinase (BTK) inhibitors are an emerging class of therapeutics in multiple
sclerosis (MS). BTK is expressed in B-cells and myeloid cells, key progenitors of which …
sclerosis (MS). BTK is expressed in B-cells and myeloid cells, key progenitors of which …
Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton's tyrosine kinase inhibitor
Background: Evobrutinib is an oral, central nervous system (CNS)-penetrant and highly
selective covalent Bruton's tyrosine kinase inhibitor under clinical development for patients …
selective covalent Bruton's tyrosine kinase inhibitor under clinical development for patients …
BTK inhibition limits microglia-perpetuated CNS inflammation and promotes myelin repair
A Geladaris, S Torke, D Saberi, YB Alankus… - Acta …, 2024 - Springer
In multiple sclerosis (MS), persisting disability can occur independent of relapse activity or
development of new central nervous system (CNS) inflammatory lesions, termed chronic …
development of new central nervous system (CNS) inflammatory lesions, termed chronic …
From progression to progress: The future of multiple sclerosis
Significant advances have been made in the diagnosis and treatment of multiple sclerosis in
recent years yet challenges remain. The current classification of MS phenotypes according …
recent years yet challenges remain. The current classification of MS phenotypes according …
Efficacy and safety results after> 3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a …
X Montalban, K Piasecka-Stryczynska… - Multiple Sclerosis …, 2024 - journals.sagepub.com
Background: Evobrutinib–an oral, central nervous system (CNS)-penetrant, and highly
selective Bruton's tyrosine kinase inhibitor–has shown efficacy in a 48-week, double-blind …
selective Bruton's tyrosine kinase inhibitor–has shown efficacy in a 48-week, double-blind …
Bruton's Tyrosine Kinase Inhibitors for Multiple Sclerosis Treatment: A New Frontier.
BM Greenberg - Neurologic Clinics, 2023 - europepmc.org
Multiple sclerosis (MS) can cause significant disability to patients via relapse-associated
worsening and progression independent of relapses. The causes of neuronal and myelin …
worsening and progression independent of relapses. The causes of neuronal and myelin …
[PDF][PDF] Bruton tyrosine kinase inhibition in multiple sclerosis
30 PRACTICAL NEUROLOGY FEBRUARY 2022 lymphocytic leukemia and mantle cell
lymphoma. Despite its effectiveness for B-cell malignancies, resistance and off-target …
lymphoma. Despite its effectiveness for B-cell malignancies, resistance and off-target …